A Real-Life, Multicenter, Observational Study analyzing Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary) ; Adalimumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2023 New trial record
- 01 Mar 2023 Results published in the Inflammatory Bowel Diseases